Medicare Is Denying More Claims Than Ever -- Here's How to Fight Back

4.1 million Medicare Advantage prior-authorization requests were fully or partially denied in 2024; appeals are underused but the majority of appeals result in full or partial overturns. The article provides a six-step appeals playbook (understand the denial, act quickly—typically 120 days for Original Medicare—get your doctor involved, file CMS-20027 redetermination, CMS-20033 reconsideration, then OMHA-100 ALJ hearing) and cites resources (Medicare Rights Center helpline, SHIP, and authorization form OMB-0938-0930) to assist beneficiaries.

Analysis

A sustained rise in claim denials and appeals is creating a durable, addressable demand stream for automation, natural-language understanding, and case-management orchestration across providers and vendors. The work is not one-off: models must handle heterogeneous EHR formats, repeated inference at scale, human-in-the-loop workflows, and compliant logging — a profile that favors high-throughput accelerators and recurring cloud spend over simple point products. Expect material revenue re‑mixing rather than zero-sum margin transfer: specialist RCM vendors and software integrators capture service dollars, while hyperscalers and GPU vendors capture the infrastructure spend to run those models.

Second-order winners include outsourced appeals managers, mid-market hospital systems that can monetize improved cash flow by reducing denials, and enterprise software players that bundle prior‑auth automation into broader revenue-cycle suites. Conversely, pure-play Medicare Advantage insurers and legacy, in-house appeals teams face margin pressure from higher reversal rates and rising customer-acquisition/retention costs; regulatory scrutiny that raises transparency standards would amplify that pressure. The timeline for meaningful adoption is asymmetric: initial ROI for large systems shows within 6–12 months, but broad market penetration and the attendant infrastructure lift take 12–36 months.

Key risks and catalysts: (1) legislative or CMS reforms that shorten appeal windows or mandate faster adjudication would blunt the secular services opportunity; (2) rapid maturation of low-cost inference accelerators or end-to-end SaaS offerings could cap pricing power for premium GPU vendors; (3) a meaningful ALJ backlog reduction or insurer operational fixes would reduce addressable spend. Monitor monthly ALJ clearance rates, elective prior‑auth volumes, and procurement cycles at large health systems as near-term catalysts.

Contrarian view: the market underestimates the stickiness of appeals automation once integrated into billing workflows — each overturned denial creates a repeatable ruleset that compounds automation benefits. That favors capex/light SaaS/transactional businesses (RCM platforms, API-first prior-auth vendors) and infrastructure suppliers who can guarantee latency, compliance, and auditability, rather than one-off consulting engagements.

Key Decisions for Investors

• Buy NVDA 9–15 month call spread to capture healthcare AI inference growth — allocate 2–3% of portfolio. Use a moderately bullish structure (buy near-dated ATM calls, sell higher strike) to cap premium while participating in 30–60% upside if enterprise GPU spend accelerates; downside is limited to premium paid.
• Add a 3–12 month overweight in R1 RCM (RCM) or comparable listed revenue-cycle vendor — 2–4% position. Thesis: direct beneficiary of outsourced appeals and higher denial reversal volumes; set a 20–25% stop if contract cadence or guidance disappoints.
• Pair trade: long ORCL (Cerner exposure) or UNH (Optum) 6–18 months and short a concentrated Medicare Advantage pure-play (e.g., HUM) — equal notional sizes at 1–2% net exposure. Rationale: integrated platforms can upsell workflow automation and capture service margin while pure MA players absorb higher appeal costs; close pair if CMS policy signals reduce MA reimbursement headwinds.